Dollar Amounts
USD (Millions)
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Assets | $239 | $255 | $253 | $254 | $406 |
| Liabilities | $78 | $75 | $67 | $77 | $173 |
| Equity | $161 | $179 | $186 | $176 | $234 |
Balance sheet data in USD (millions)
Doing some research...
Edwyn
Over the past five years, Eagle Pharmaceuticals, Inc. has shown a significant growth in its financial position. Total assets have increased steadily from $238.603 million in 2018 to $406.16 million in 2022, indicating the company's expansion and potential for future growth opportunities. This growth in assets could be attributed to strategic investments, acquisitions, or successful product launches that have boosted the company's overall value. Simultaneously, total liabilities have also increased, although not as steeply as assets, rising from $77.841 million in 2018 to $172.6 million in 2022. This suggests that the company has taken on additional debt to finance its growth initiatives. However, it's important to note that Eagle Pharmaceuticals has managed to maintain a healthy stockholders' equity position throughout the period, with fluctuations but overall growth from $160.762 million in 2018 to $233.56 million in 2022. This indicates that the company has been able to generate returns for its shareholders and sustain a strong financial standing relative to its debt levels. Overall, the company's financial performance indicates a positive trajectory, with a focus on balancing growth with financial stability.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.